Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
August 7, 2018 7:30 AM EDTPlan to Open Expansion Cohorts in Phase 1 Trial of SY-1365 in Fall of 2018; Expansion to Focus on Ovarian and Breast Cancer Patient Populations as Single Agent and in Combination
Expect to Report Initial Clinical Data from Combination Arms of Phase 2 Trial of SY-1425 and Dose Escalation Portion of Phase 1 Trial of SY-1365 in Fourth Quarter of 2018
EMA Grants SY-1425 Orphan Drug Designation for Treatment of AML
Management to Host Conference Call at 8:30 AM ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:... More
